The European Biological Variation Study (EuBIVAS): A summary report

Anna Carobene, Aasne K. Aarsand, William A. Bartlett, Abdurrahman Coskun, Jorge Diaz-Garzon, Pilar Fernandez-Calle, Elena Guerra, Niels Jonker, Massimo Locatelli, Mario Plebani, Sverre Sandberg, Ferruccio Ceriotti

Research output: Contribution to journalReview articlepeer-review

Abstract

Biological variation (BV) data have many important applications in laboratory medicine. Concerns about quality of published BV data led the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 1st Strategic Conference to indicate need for new studies to generate BV estimates of required quality. In response, the EFLM Working Group on BV delivered the multicenter European Biological Variation Study (EuBIVAS). This review summarises the EuBIVAS and its outcomes. Serum/plasma samples were taken from 91 ostensibly healthy individuals for 10 consecutive weeks at 6 European centres. Analysis was performed by Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000, c702 and e801 (proteins and tumor markers/hormones respectively), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers). A strict preanalytical and analytical protocol was applied. To determine BV estimates with 95% CI, CV-ANOVA after analysis of outliers, homogeneity and trend analysis or a Bayesian model was applied. EuBIVAS has so far delivered BV estimates for 80 different measurands. Estimates for 10 measurands (Non-HDL Cholesterol, S100-β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, free, conjugated and %free prostate-specific antigen), prior to EuBIVAS, have not been available. BV data for creatinine and troponin I were obtained using two analytical methods in each case. The EuBIVAS has delivered high-quality BV data for a wide range of measurands. The BV estimates are for many measurands lower than those previously reported, having an impact on the derived analytical performance specifications and reference change values.

Original languageEnglish
JournalClinical Chemistry and Laboratory Medicine
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • analytical performance specification
  • biological variation
  • EuBIVAS
  • reference change values

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'The European Biological Variation Study (EuBIVAS): A summary report'. Together they form a unique fingerprint.

Cite this